Study Enrollment

Your details will not be published or shared.

Clinical Trial

(Lionheart21) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

This study is for kidney transplant patients have not had CMV infection. These patients have received a kidney from a donor who has tested positive for CMV infection. This puts them at great risk for getting CMV infection. This study will test the safety and effects of a new drug in treating and preventing cytomegalyvirus (CMV) infections in these patients.

Eligibility Criteria

  • Adults agees 18 through 69 years of age CMV sero-negative before transplant Receive a kidney transplant from donor who had documented CMV infection

Contact Information

    Ravi Mallavarapu, MBBS

    (706) 721-2861